StoryResearch
NeuroPace presents NAUTILUS trial data showing 77% seizure reduction for generalized epilepsy at AAN
NeuroPace announced 18-month results from the NAUTILUS trial at the American Academy of Neurology Annual Meeting. The study showed a statistically significant 77% median reduction in generalized tonic-clonic seizures, and the RNS System was the first therapy to demonstrate that idiopathic generalized epilepsy seizures can be safely detected and treated via centromedian nucleus stimulation.